We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: phase 2 trial
MedXY News
EnglishTag

phase 2 trial

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial
newsHóa xạ trị tiền phẫu thuậtlocal control

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial

By MedXY|Jun 10, 2026

Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial
newsHóa xạ trị tiền phẫu thuật
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
local control

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial

By MedXY|Jun 10, 2026

A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism
Diabetes & EndocrinologyendocrinologyHypothyroidism

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism

By MedXY|Jun 5, 2026

A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.

Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common
Hematology-OncologyamivantamabEGFR MET

Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common

By MedXY|Apr 20, 2026

In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.

CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial
Hematology-Oncologyimmune thrombocytopeniaphase 2 trial

CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial

By MedXY|Oct 31, 2025

The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study
GastroenterologyBiliary tract cancerGEMOX

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

By MedXY|Oct 15, 2025

The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63%

Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy
Clinical UpdatesAdult T-cell leukemia/lymphomaphase 2 trial

Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy

By MedXY|Oct 8, 2025

A phase 2 study demonstrated that combining mogamulizumab with CHOP chemotherapy improves progression-free survival in older patients with adult T-cell leukemia/lymphoma, highlighting a promising first-line option.

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data
Clinical Updatesbiologic therapyCrohn’s disease

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY|Oct 1, 2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities